Drug Trial Radar · NCT06126237
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 28, 2024
Primary completion
Feb 28, 2026
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.
Conditions
- Multiple Myeloma
Interventions
CM313 injectionBiological
CM313, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: up to 18 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.